Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
NCT ID: NCT02201797
Last Updated: 2015-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2014-10-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRCP Diagnoses EHCC Better When Combined DWI
NCT01595217
An Investigational Scan (MR DENSE) in Detecting Early Chemotherapy-Related Liver Injury Before Surgery in Patients With Resectable Colorectal Liver Metastases
NCT05059717
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
NCT01411579
Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
NCT00527891
DCE-MRI for Assessment of Response to TACE of HCC
NCT02878109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DCE and DWI MRI
MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
DCE MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DCE MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one liver tumor should be \> 2cm in long diameter
* Patients with viable tumor proven in the other imaging modalities
Exclusion Criteria
* Presence of MRI-incompatible metallic objects or implanted medical devices in body
* Renal failure, as determined by glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2
* Weight greater than that allowable by the MRI table
* Chemotherapy within 28 days prior to enrollment
* Prior external radiation therapy to the liver, prior transarterial chemoembolization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bracco Diagnostics, Inc
INDUSTRY
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyung Won Kim
Assistance Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung Won Kim, M.D.
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-0060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.